Arix Bioscience a diversified portfolio and an IRR of 20% since inception (Analyst Interview)

Arix Bioscience plc (LON:ARIX) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joins DirectorsTalk. Martin explains how Arix differs from other investment vehicles, how it has performed well since it released its interim results, trading relative to the NAV, narrowing the discount, the risks involved and what to expect from the company looking forward.

Questions we ask Dr Martin Hall:

Q1: Can you tell us what Arix does and how it differs from other investment vehicles?
Q2: The shares of Arix Bioscience have performed well since it released its interim results for 2020. Can you say what has been behind this movement?
Q3: So, how are the shares trading relative to the NAV?
Q4: What do you think will make this discount narrow?
Q5: What are the risks?
Q6: What is coming up in the near future?

Arix Bioscience is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Arix Bioscience: 32% IRR since inception in 2016

    Arix Bioscience plc (LON:ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech investing. ARIX minimises risk through

    Hardman & Co

    Arix Bioscience: Artios attracts Merck KGaA in deal up to $7bn

    Arix Bioscience plc (LON:ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech investing. ARIX minimises risk through

    Hardman & Co

    Arix Bioscience: Hitting the jackpot

    Arix Bioscience plc (LON:ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech investing. ARIX minimises risk through

    Hardman & Co

    Arix Bioscience: Realising the valuation disconnect

    Arix Bioscience plc (LON:ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech investing. ARIX minimises risk through

    Hardman & Co

    Arix Bioscience 1Q’20 portfolio update

    Arix Bioscience PLC (LON:ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech investing. ARIX minimises risk through

    Hardman & Co

    Arix Bioscience Resetting the stage

    Arix Bioscience PLC (LON:ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech investing. ARIX minimises risk through

    Hardman & Co

    Arix Bioscience Fiscal 2019 – moving with the times

    Arix Bioscience (LON:ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech investing. Arix minimises risk through its

    Hardman & Co

    Arix Bioscience: Multiple inflection points in 2020

    Arix Bioscience plc (LON:ARIX) is the topic of conversation when Dr Dorothea Hill, Analyst at Hardman & Co joins DirectorsTalk. Having recently initiated on Arix Bioscience Dorothea explains the key takeaways retail investors should be aware of,

    Hardman & Co

    Arix Bioscience With high risk can come high reward

    Arix Bioscience (Arix) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech investing. Arix minimises risk through its